MENU
+Compare
SCYX
Stock ticker: NASDAQ
AS OF
Nov 21, 04:59 PM (EDT)
Price
$0.68
Change
-$0.01 (-1.45%)
Capitalization
28.54M

SCYX SCYNEXIS Forecast, Technical & Fundamental Analysis

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs... Show more

SCYX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for SCYX with price predictions
Nov 21, 2025

SCYX in +18.89% Uptrend, advancing for three consecutive days on November 20, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SCYX advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SCYX's RSI Indicator exited the oversold zone, of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where SCYX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 20, 2025. You may want to consider a long position or call options on SCYX as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SCYX just turned positive on November 18, 2025. Looking at past instances where SCYX's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCYX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SCYX broke above its upper Bollinger Band on November 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SCYX entered a downward trend on November 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.783) is normal, around the industry mean (17.139). P/E Ratio (0.905) is within average values for comparable stocks, (72.460). SCYX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.930). SCYX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (11.468) is also within normal values, averaging (52.518).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SCYX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCYX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
SCYX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

SCYX is expected to report earnings to fall 162.76% to 10 cents per share on April 01

SCYNEXIS SCYX Stock Earnings Reports
Q4'25
Est.
$0.11
Q3'25
Beat
by $0.03
Q2'25
Beat
by $0.06
Q1'25
Beat
by $0.10
Q4'24
Beat
by $0.06
The last earnings report on November 05 showed earnings per share of -17 cents, beating the estimate of -20 cents. With 1.02M shares outstanding, the current market capitalization sits at 28.54M.
A.I. Advisor
published General Information

General Information

a company which engages in discovery, development and commercialization of novel anti infectives

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
1 Evertrust Plaza
Phone
+1 201 884-5485
Employees
29
Web
https://www.scynexis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CCCC2.430.05
+2.31%
C4 Therapeutics
XNCR15.850.28
+1.77%
Xencor
MYND0.620.01
+1.52%
Myndai
MSGS216.272.55
+1.19%
Madison Square Garden Sports Corp
MMC180.921.97
+1.10%
Marsh & McLennan Companies

SCYX and Stocks

Correlation & Price change

A.I.dvisor tells us that SCYX and ELAN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
-1.45%
ELAN - SCYX
29%
Poorly correlated
+4.76%
CRDL - SCYX
28%
Poorly correlated
+1.08%
ACET - SCYX
27%
Poorly correlated
+3.95%
SIGA - SCYX
25%
Poorly correlated
+1.39%
AKAN - SCYX
25%
Poorly correlated
-2.55%
More

Groups containing SCYX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
-1.45%
Pharmaceuticals: Generic
industry (214 stocks)
22%
Poorly correlated
+1.55%